EMD Serono, the U.S. division of Merck KGaA, is parting ways with an undisclosed number of employees. The layoffs will affect research staff at the company’s offices in Durham, North Carolina.
All entries for: Immune Diseases
January 12, 2026
InflaRx
Discontinued Research, Layoffs
Jena, Germany
51-200 employees
InflaRx is cutting approximately 30% of its employees in a bid to streamline its spending and pour more of its resources into its lead candidate. To accompany the layoffs, InflaRx will also pull money from its investigational antibody Gohibic, according to a press announcement Jan. 8.
Disease Area: Chronic Disease, Immune Diseases, Infectious Diseases
Drug Type: Biologic, Small Molecule
January 3, 2026
GSK
Layoffs
San Francisco, CA
50,001+ employees
Up to 350 people across GSK’s U.S. and U.K. workforces could lose their jobs as the pharma reorients its investments with its priorities. The layoffs are expected to affect fewer than 70 individuals in the US, and fewer than 50 in the UK, according to Fierce.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
December 18, 2025
Intercept Pharmaceuticals
Layoffs
Morristown, NJ
201-500 employees
Months after withdrawing its only commercial product, Ocaliva, from the market, Intercept Pharmaceuticals is letting go of 146 employees from its New Jersey campus, according to a Worker Adjustment and Retraining Notification (WARN) Act posting.
Disease Area: Gastrointestinal, Immune Diseases
Drug Type: Small Molecule
November 25, 2025
Novartis
Layoffs
Basel, Switzerland
10,001-50,000 employees
Novartis will cut 550 full-time jobs at a facility in Switzerland by the end of 2027. The cuts come as the pharma company is ending production of tablets, capsules, and sterile medicine packaging at a plant in Stein, Switzerland.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
November 18, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck is letting go of 204 employees from its Rahway, New Jersey location, continuing its aggressive layoff spree in recent months.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 17, 2025
Bristol Myers Squibb
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb has announced another round of layoffs, affecting 110 employees at the Lawrence Township site.
Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 13, 2025
Fate Therapeutics
Neutral Outlook
San Diego, CA
51-200 employees
The Inflation Reduction Act of 2022 (the IRA), for example, includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025, eliminating the prescription drug coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of an HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge.
Disease Area: Chronic Disease, Immune Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule